Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 21:2018:5982575.
doi: 10.1155/2018/5982575. eCollection 2018.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands

Affiliations

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands

Danique L M van Broekhoven et al. Sarcoma. .

Abstract

Introduction: Nonsurgical management of patients with desmoid-type fibromatosis (DF) is increasing. This study tries to provide insight on type, usage, and outcome of first-line nonsurgical management strategies.

Patients and methods: From the Dutch Pathology Registry (PALGA), patients with extra-abdominal or trunk/abdominal wall DF, diagnosed between 1993 and 2013, were identified. First-line treatment was analyzed. Best response (BR) using RECIST criteria from start of treatment/surveillance until change of treatment or last follow-up was analyzed.

Results: Ninety-one of the 1141 identified patients had first-line nonsurgical management. The percentage of patients treated nonsurgically increased from 0.6% in 1993-1998 to 12.8% in 2009-2013. Thirty-seven patients had surveillance (41%), 35 radiotherapy (38%), and 19 systemic treatment (21%). BR for surveillance was complete response (CR) in 2/37, partial response (PR) in 4/37, stable disease (SD) in 21/37, progressive disease (PD) in 5/37, and unknown in 5/37 patients. BR for radiotherapy was CR in 4/35, PR in 11/35, SD in 16/35, and unknown in 4/35. BR for systemic treatment was CR in 1/19, PR in 1/19, SD in 10/19, PD in 2/19, and unknown in 5/19. Totally, 91% of patients did not progress.

Discussion: Given the low percentage (9%) of PD of nonsurgical management, these data can be used in shared decision making with the patient regarding optimal treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram of patient selection.

References

    1. Fletcher C. D. M., Bridge J. A., Hogendoorn P., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th. Lyon, France: IARC Press; 2013.
    1. Fiore M., RImareix F., Mariani L., et al. Desmoid-Type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Annals of Surgical Oncology. 2009;16(9):2587–2593. doi: 10.1245/s10434-009-0586-2. - DOI - PubMed
    1. Salas S., Dufresne A., Bui B., et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. Journal of clinical oncology. Journal of Clinical Oncology. 2011;29(26):3553–3558. doi: 10.1200/jco.2010.33.5489. - DOI - PubMed
    1. van Broekhoven D. L., Grünhagen D. J., den Bakker M. A., van Dalen T., Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Annals of Surgical Oncology. 2015;22(9):2817–2823. doi: 10.1245/s10434-015-4632-y. - DOI - PMC - PubMed
    1. Kasper B., Baumgarten C., Bonvalot S., et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise–a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. European Journal of Cancer. 2015;51(2):127–136. doi: 10.1016/j.ejca.2014.11.005. - DOI - PubMed

LinkOut - more resources